LGALS1 and hepatocellular carcinoma: While miR-22 treatment reduced the liver-to-body weight ratio to 8%, the ratio was 18% in the presence of AAV9-Gal-1, partially inhibiting the anti-HCC effect of miR-22 (Fig. 5B).